Amgen posts results of Phase 3 erenumab trial in pediatric chronic migraine
The study, completed with 284 participants, evaluated erenumab in children 6 to <12 years and adolescents 12 to <18 years with chronic migraine. Results were first posted on ClinicalTrials.gov on October 28, 2026.
Primary source
ClinicalTrials.gov results record, October 28, 2026
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
Read the source: Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation